PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
News

Positive Phase III results for plant-based COVID-19 vaccine

Medicago and GlaxoSmithKline (GSK) have announced positive efficacy and safety results from the global Phase III placebo-controlled efficacy study of Medicago’s plan...
Continue Reading →
News

Positive results for GSK’s anaemia drug daprodustat

GlaxoSmithKline (GSK) has revealed positive data for its investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) daprodustat in patients...
Continue Reading →
News

Opdivo plus chemo improves event-free survival in NSCLC patients

Bristol Myers Squibb (BMS) has announced that its PD-1 inhibitor Opdivo (nivolumab) plus chemotherapy improved event-free survival in a Phase III trial in patients w...
Continue Reading →
News

AZ announces US fast track designation for IL-5 inhibitor Fasenra

AstraZeneca’s IL-5 inhibitor Fasenra (benralizumab) has received a fast-track designation from the US Food and Drug Administration for the treatment of eosinoph...
Continue Reading →
News

MHRA licenses Ryeqo for symptoms of uterine fibroids

The Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Gedeon Richter UK’s Ryeqo (relugolix combination therapy) for the treatment of moderate t...
Continue Reading →
News

AstraZeneca’s long-acting antibody combination treats and prevents COVID-19

Positive high-level results from the TACKLE Phase III COVID-19 treatment trial have shown that AstraZeneca’s AZD7442, a long-acting antibody (LAAB) combination, achi...
Continue Reading →
News

Positive Phase III results for Lynparza plus abiraterone in metastatic prostate cancer

Positive high-level results from the PROpel Phase III trial have shown that AstraZeneca and MSD’s Lynparza (olaparib), in combination with abiraterone, dem...
Continue Reading →
News

New tezepelumab data shows improvements for severe asthma subgroup

AstraZeneca and Amgen’s thymic stromal lymphopoietin (TSLP) blocker tezepelumab has demonstrated new improvements for patients with severe asthma and comorbid nasal ...
Continue Reading →
News

Phase III data for Jardiance shows improvement in HFpEF patients

Results from the EMPEROR-Preserved Phase III trial have shown that Jardiance (empagliflozin) demonstrated a 21% relative risk reduction of cardiovascular death or ho...
Continue Reading →
News

Dupixent trial meets endpoints for childhood eczema

The Phase III trial for Sanofi/Regeneron's Dupixent (dupilumab) plus topical corticosteroids (TCS) for the treatment of moderate-to-severe atopic dermatitis (eczema)...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026